Biologic Agents in the Treatment of Crohn’s Disease:
A Case-Based Discussion of Optimal Management Strategies
 

EDUCATIONAL OBJECTIVES

At the end of this program, attendees should be better able to:

• Identify the appropriate patient with CD who is an optimal candidate to receive biologic therapy
• Compare and contrast the efficacy of selected biologic agents in the induction and maintenance of remission in patients with CD, including healing of fistulizing disease, tapering of corticosteroids, and reduction in the incidence of surgery and hospitalizations
• Outline the data supporting the use of a second biologic agent in a CD patient who fails initial biologic therapy
• Describe the safety profiles of selected biologic agents and the steps that can be taken to mitigate adverse events associated with these agents

TARGET AUDIENCE

This program is intended for gastroenterology professionals (physicians, physician assistants, nurse practitioners, and nurses) interested in the management of patients with CD.

ACCREDITATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Rosalind Franklin University of Medicine & Science and Scientific Frontiers, Inc.

Rosalind Franklin University of Medicine & Science is accredited by the ACCME to provide continuing medical education for physicians. Rosalind Franklin University of Medicine & Science designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

SUPPORT STATEMENT

Jointly sponsored by The Chicago Medical School at Rosalind Franklin University of Medicine & Science and Scientific Frontiers, Inc.

Supported by an educational grant from Abbott